supp.fit

Lutein and Omega-3 Fatty Acids: study protocols

15 study groups took Lutein together with Omega-3 Fatty Acids. These are the doses the studies gave. They are not a recommendation.

Lutein: what the research found →

Dose per serving from research: Lutein

15 study groups in 13 studies say how much Lutein participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 87% of 15 study groups.

Daily doseStudy groups
5 mg or less
1
5 mg to 10 mg
13
10 mg to 25 mg
1

Dose per serving from research: Omega-3 Fatty Acids

12 study groups in 11 studies say how much Omega-3 Fatty Acids participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 50% of 12 study groups.

Daily doseStudy groups
50 mg or less
1
50 mg to 100 mg
2
100 mg to 250 mg
1
250 mg to 500 mg
1
500 mg to 1 g
6
1 g to 2.5 g
1

Commonly used together

14 of 15 study groups took Lutein and Omega-3 Fatty Acids with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Zeaxanthin
13
Docosahexaenoic Acid
6
Vitamin E
5

15 study groups

Study
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
10 mg650 mg5 years—
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3
2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified
10 mg1 g1789 days—
No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18
2019 · Lutein and zeaxanthin plus omega-3 fatty acids · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye
10 mg1 g5 years—
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
10 mg100 mg12 weeks96
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
10 mg100 mg24 weeks40
TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD
2007 · Sham MCS and nutritional supplement · Adults aged 50–90 with dry age-related macular degeneration in at least one eye
8 mg300 mg24 weeks37
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
10 mg650 mg5 years—
A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on neural processing speed and efficiency
2014 · Multi · Healthy adults aged 18–32 years
8 mg190 mg120 days25
Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease
2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported
10 mg650 mg1 year50
Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial
2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified
10 mg30 mg1 year—
Oral Lutein Supplementation Enhances Macular Pigment Density and Contrast Sensitivity but Not in Combination With Polyunsaturated Fatty Acids
2015 · lutein and antioxidant supplement in combination with PUFA · Patients with age-related maculopathy
10 mg—26 weeks—
Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study
2013 · D2 (twice daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified
20 mg—1 year55
Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study
2013 · D1 (once daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified
10 mg—1 year50
Consumption of Hen Eggs Enriched with n-3 Polyunsaturated Fatty Acids, Selenium, Vitamin E and Lutein Incites Anti-Inflammatory Conditions in Young, Healthy Participants - A Randomized Study
2022 · 4Nutri group · Young, healthy participants; age range and sex not stated
1.85 mg1.03 g3 weeks20
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
10 mg650 mg5 years—